|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Medical Oncology (Drs. Toh, Lim, and Leong), Department of Therapeutic Radiology (Drs. Fong and Wee), Division of Clinical Trials and Epidemiological Sciences (Drs. Wong and Tan), National Cancer Center, Singapore.
Correspondence to: Eng-Huat Tan, MD, Department of Medical Oncology, National Cancer Center, 11 Hospital Drive, Singapore 169610, Tel: 65-64368171, Fax: 65-62272759, e-mail: dmoteh{at}nccs.com.sg
Study objectives: There are fundamental differences in characteristics between smokers and nonsmokers with non-small cell lung cancer (NSCLC). We aim to study the impact of smoking status on the behavior of the disease, and to identify differences in outcome between the two groups.
Design: A retrospective analysis was done of patients with NSCLC seen during the period from January 1999 to August 2002. Clinical characteristics, survival outcome, and response to treatment were reviewed and compared between the smokers and nonsmokers.
Setting: Department of Medical Oncology, National Cancer Center.
Results: Of 317 patients analyzed, 117 patients (36.3%) were nonsmokers. Among the nonsmokers, 74.5% had adenocarcinoma and 73.9% were women. The smokers had poorer performance status, reported more weight loss, and had a higher mean age at diagnosis of almost 8 years than nonsmokers. One hundred eighty-seven patients (59%) had died as of December 31, 2002. The nonsmokers had a longer median survival, although this was not statistically significant. There were no statistically significant differences in survival and response to chemotherapy between the two groups after adjusting for known prognostic factors.
Conclusions: Despite the known differences in mutational spectra and clinical characteristics between smokers and nonsmokers with NSCLC, no differences in terms of response to chemotherapy and survival outcome were observed. This could imply that this disease is equally aggressive in these two groups. More research is needed to further delineate and characterize the differences between these two etiologically different forms of NSCLC.
Key Words: chemotherapy non-small cell lung cancer smoking survival
This article has been cited by other articles:
![]() |
C.-K. Toh, F. Gao, W.-T. Lim, S.-S. Leong, K.-W. Fong, S.-P. Yap, A. A.L. Hsu, P. Eng, H.-N. Koong, A. Thirugnanam, et al. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity J. Clin. Oncol., May 20, 2006; 24(15): 2245 - 2251. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Yoshino, D. Kawano, T. Oba, K. Yamazaki, T. Kometani, and Y. Maehara Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma Ann. Thorac. Surg., April 1, 2006; 81(4): 1189 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Gritz, C. Dresler, and L. Sarna Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2287 - 2293. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Paull, G. M. Updyke, M. A. Baumann, H. W. Chin, A. G. Little, and S. A. Adebonojo Alcohol Abuse Predicts Progression of Disease and Death in Patients with Lung Cancer Ann. Thorac. Surg., September 1, 2005; 80(3): 1033 - 1039. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |